Calcivis Secures £4.5 Million for Dental Innovation
Calcivis, a pioneering medical devices company based in Edinburgh, Scotland, has recently achieved a significant milestone by securing £4.5 million in new equity and grant funding. This financial boost comes from a consortium of backers, including Archangel Investors and the Scottish Investment Bank, who have contributed an additional £2.6 million. Furthermore, Calcivis has successfully obtained €2.6 million (approximately £1.9 million) in grant funding from the European Commission through its Horizon 2020 SME Instrument programme. This infusion of capital highlights the confidence investors have inCalcivis's innovative approach to dental health technology.
The primary aim of this funding is to bolster the development and commercialization efforts of the Calcivis® Caries Activity Imaging System.
This sophisticated in-clinic device integrates a highly sensitive intraoral camera with cutting-edge application technology. This system is designed to apply a precise amount of a proprietary disclosing solution, which contains a unique photoprotein, directly onto the surface of the teeth. Such an advancement promises to revolutionize how dental professionals assess and manage caries, providing a more accurate and effective means of detecting dental decay at early stages.
Under the leadership of CEO Adam Christie, Calcivis is now focusing on several crucial steps to ensure the successful commercialization of their innovative system in Europe. In addition, the company aims to navigate the regulatory landscape to obtain approval for marketing their product in the US. Having already achieved a CE Mark in Europe and reported that their first clinical study successfully met its primary performance endpoint for identifying early active caries lesions, Calcivis is well-positioned for future growth and impact in the field of dental health.
Click here for a full list of 7,589+ startup investors in the UK